Xcout Intel
Bellerophon Therapeutics, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Bellerophon Therapeutics, Inc. among biotech companies — ranked by similarity to what Bellerophon Therapeutics, Inc. actually does, not by market-cap band.
Subscribe to see Bellerophon Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Bellerophon Therapeutics, Inc.
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that engages in the development of products to address pulmonary hypertension related to interstitial lung disease.
Bellerophon Therapeutics, Inc. at a glance
Bellerophon Therapeutics, Inc. is a biotech company headquartered in United States. It has raised at least $25M across the 2 funding rounds on record. Its most recent funding round raised $23.4M in September 2017. Xcout tracks 13 named people at Bellerophon Therapeutics, Inc., including Leigh-Anne Claase (Chief Executive Officer).
Bellerophon Therapeutics, Inc. leadership
- Leigh-Anne ClaaseChief Executive Officer
- Con HoraitisExecutive Director Technology
- Emma BarkerExecutive Director Sales and Marketing
- Emma JuniperExecutive Director Publishing
- Sonia KokkalosExecutive Director - People & Corporate Services
- Leanne RussellCompany Secretary
7 more named people on record for Bellerophon Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Bellerophon Therapeutics, Inc. funding rounds
At least $25M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $23.4M | — | |
| SEC Form D filing | $1.6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Bellerophon Therapeutics, Inc. competitors
Ranked by semantic similarity — how close each company is to Bellerophon Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
AeroRx Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic obstructive pulmonary disease (COPD).
Biotechnology
Eleven P15 Inc. is a biotechnology company focused on developing early-detection biomarkers and genetically-targeted therapeutics for idiopathic pulmonary fibrosis (IPF). The company aims to improve diagnosis and treatment outcomes for patients suffering from this fatal lung disease.
Biotechnology
Pahr Therapeutics, Inc. is a biotechnology company focused on developing new treatments for pulmonary arterial hypertension (PAH). The company recently raised $14 million in seed funding to support its therapeutic development efforts.
Biotechnology
Sunterra Bio is a biopharmaceutical company focused on developing inhaled small-molecule therapies for rare pulmonary diseases. Headquartered in Carlsbad, California, the company advances targeted treatments for respiratory conditions.
Biotechnology
AllRock Bio is a clinical-stage biotechnology company headquartered in Natick, Massachusetts, dedicated to developing transformative therapies for cardiopulmonary and fibrotic conditions.
Biotechnology
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Biotechnology
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Biotechnology
Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company with principal executive offices located in Cambridge, Massachusetts. The company went public through a reverse merger and is involved in therapeutic acquisitions and development.
Biotechnology
Altesa BioSciences is a clinical-stage pharmaceutical company headquartered in College Park, Georgia. The company is dedicated to improving the lives of individuals suffering from chronic lung diseases, including conditions such as COPD and asthma.
Biotechnology
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.
Similar biotech company
Celea Therapeutics is a biopharmaceutical company focused on advancing transformative treatments for serious respiratory diseases.
Biotechnology
Expedition Therapeutics is a clinical-stage biotechnology company headquartered in San Francisco, California, developing novel oral small molecule therapies for serious inflammatory and respiratory diseases.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Bellerophon Therapeutics, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Bellerophon Therapeutics, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →